Ptc Therapeutics, Inc.
A biopharmaceutical company that develops treatments for rare diseases, with medicines including Sephience for PKU, Translarna and Emflaza for Duchenne muscular dystrophy, Evrysdi for spinal muscular atrophy, and the gene therapy Upstaza/Kebilidi. Founded in 1998 by RNA researcher Stuart Peltz, the company's name comes from "post-transcriptional control," the field of RNA biology it was built around.
Granted 62.4K · Sold 27.5K
Granted 486.6K · Sold 112.4K
Granted 131.8K · Sold 14.1K
Granted 479.6K · Sold 422.7K
Granted 222.5K · Sold 185.4K
Granted 90.6K · Bought 7.7K · Sold 12.3K
Granted 61.4K · Sold 23.5K
Granted 153.3K · Sold 102.7K
Granted 388.8K · Sold 368.1K
Granted 35.1K · Sold 19.5K
Granted 3.2K · Sold 1.2K
Granted 63.2K · Sold 44.0K
Granted 55.2K · Sold 36.0K
Granted 31.2K · Sold 12.0K
Granted 19.2K
Granted 90.2K · Sold 73.9K
Granted 32.7K · Sold 11.7K
Granted 96.2K · Sold 89.8K
Granted 10.3K
Granted 34.4K · Sold 28.8K
Granted 7.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schmertzler MichaelDirector · 13 transactions | — | 1.52M | 62.4K | — | 27.5K |
| Klein Matthew B.CHIEF EXECUTIVE OFFICER, Director · 42 transactions | +2216.8% | 394.0K | 486.6K | — | 112.4K |
| Peltz Stuart WalterCHIEF EXECUTIVE OFFICER, Director · 21 transactions | +118.8% | 381.1Kas of Jan 2023 | 131.8K | — | 14.1K |
| Boulding Mark ElliottEXEC. VP AND CLO · 160 transactions | +119.6% | 107.1K | 479.6K | — | 422.7K |
| Pauwels EricCHIEF BUSINESS OFFICER · 88 transactions | +154.8% | 91.0K | 222.5K | — | 185.4K |
| Gravier PierreCHIEF FINANCIAL OFFICER · 12 transactions | — | 87.3K | 90.6K | 7.7K | 12.3K |
| Golden Lee ScottEVP & CHIEF MEDICAL OFFICER · 19 transactions | — | 79.1K | 61.4K | — | 23.5K |
| Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER · 51 transactions | +266.3% | 70.2K | 153.3K | — | 102.7K |
| Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · 122 transactions | +102% | 62.9K | 388.8K | — | 368.1K |
| Hill Emily LuisaCHIEF FINANCIAL OFFICER · 13 transactions | +67% | 38.9Kas of Mar 2023 | 35.1K | — | 19.5K |
| Svoronos DawnDirector · 3 transactions | +7.2% | 29.0Kas of Jun 2022 | 3.2K | — | 1.2K |
| Zeldis Jerome BDirector · 14 transactions | +581.8% | 22.5K | 63.2K | — | 44.0K |
| Southwell David PDirector · 17 transactions | — | 22.5K | 55.2K | — | 36.0K |
| Steele Glenn Jr MD PHDDirector · 7 transactions | +581.8% | 22.5K | 31.2K | — | 12.0K |
| Smith Mary L.Director · 5 transactions | +734.8% | 21.8K | 19.2K | — | — |
| Jacobson Allan StevenDirector · 29 transactions | +316.7% | 21.5K | 90.2K | — | 73.9K |
| Young AlethiaDirector · 10 transactions | — | 21.1K | 32.7K | — | 11.7K |
| Reeve EmmaDirector · 48 transactions | +146.4% | 10.7K | 96.2K | — | 89.8K |
| Bell William F. Jr.Director · 3 transactions | — | 10.3Kas of Feb 2024 | 10.3K | — | — |
| Okey StephanieDirector · 13 transactions | +730.7% | 8.0K | 34.4K | — | 28.8K |
| Chutter Jessica CarolineDirector · 2 transactions | — | 7.3K | 7.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.58M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.